BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35122631)

  • 1. Role of chromogranin A-derived fragments after resection of nonfunctioning pancreatic neuroendocrine tumors.
    Andreasi V; Partelli S; Manzoni MF; Muffatti F; Di Filippo L; Crippa S; Corti A; Falconi M
    J Endocrinol Invest; 2022 Jun; 45(6):1209-1217. PubMed ID: 35122631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between preoperative Vasostatin-1 and pathological features of aggressiveness in localized nonfunctioning pancreatic neuroendocrine tumors (NF-PanNET).
    Andreasi V; Partelli S; Manzoni M; Muffatti F; Colombo B; Corti A; Falconi M
    Pancreatology; 2019 Jan; 19(1):57-63. PubMed ID: 30470614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasostatin-1: A novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms.
    Corsello A; Di Filippo L; Massironi S; Sileo F; Dolcetta Capuzzo A; Gemma M; Carlucci C; Cusini C; Colombo B; Dallatomasina A; Franchi GM; Corti A; Manzoni MF
    PLoS One; 2018; 13(5):e0196858. PubMed ID: 29723285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating Neuroendocrine Gene Transcripts (NETest): A Postoperative Strategy for Early Identification of the Efficacy of Radical Surgery for Pancreatic Neuroendocrine Tumors.
    Partelli S; Andreasi V; Muffatti F; Schiavo Lena M; Falconi M
    Ann Surg Oncol; 2020 Oct; 27(10):3928-3936. PubMed ID: 32253675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors.
    Pulvirenti A; Rao D; Mcintyre CA; Gonen M; Tang LH; Klimstra DS; Fleisher M; Ramanathan LV; Reidy-Lagunes D; Allen PJ
    HPB (Oxford); 2019 May; 21(5):612-618. PubMed ID: 30366884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standard pre- and postoperative determination of chromogranin a in resectable non-functioning pancreatic neuroendocrine tumors--diagnostic accuracy: NF-pNET and low tumor burden.
    Jilesen AP; Busch OR; van Gulik TM; Gouma DJ; Nieveen van Dijkum EJ
    Dig Surg; 2014; 31(6):407-14. PubMed ID: 25572908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors.
    Shanahan MA; Salem A; Fisher A; Cho CS; Leverson G; Winslow ER; Weber SM
    J Surg Res; 2016 Mar; 201(1):38-43. PubMed ID: 26850182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
    Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
    Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases.
    Han X; Zhang C; Tang M; Xu X; Liu L; Ji Y; Pan B; Lou W
    Eur J Gastroenterol Hepatol; 2015 May; 27(5):527-35. PubMed ID: 25822862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative assessment of microvessel density in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs).
    Battistella A; Partelli S; Andreasi V; Marinoni I; Palumbo D; Tacelli M; Lena MS; Muffatti F; Mushtaq J; Capurso G; Arcidiacono PG; De Cobelli F; Doglioni C; Perren A; Falconi M
    Surgery; 2022 Oct; 172(4):1236-1244. PubMed ID: 35953308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors.
    Dam G; Grønbæk H; Sorbye H; Thiis Evensen E; Paulsson B; Sundin A; Jensen C; Ebbesen D; Knigge U; Tiensuu Janson E
    Neuroendocrinology; 2020; 110(3-4):217-224. PubMed ID: 31578011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas.
    Qiao XW; Qiu L; Chen YJ; Meng CT; Sun Z; Bai CM; Zhao DC; Zhang TP; Zhao YP; Song YL; Wang YH; Chen J; Lu CM
    BMC Endocr Disord; 2014 Aug; 14():64. PubMed ID: 25099181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution.
    Massironi S; Rossi RE; Casazza G; Conte D; Ciafardini C; Galeazzi M; Peracchi M
    Neuroendocrinology; 2014; 100(2-3):240-9. PubMed ID: 25428270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical usefulness of plasma chromogranin a in pancreatic neuroendocrine neoplasm.
    Paik WH; Ryu JK; Song BJ; Kim J; Park JK; Kim YT; Yoon YB
    J Korean Med Sci; 2013 May; 28(5):750-4. PubMed ID: 23678268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of surgery for metastatic pancreatic neuroendocrine tumor: a contemporary evaluation matching for chromogranin a level.
    Concors SJ; Sinnamon AJ; Ecker BL; Metz DC; Vollmer CM; Fraker DL; Roses RE
    HPB (Oxford); 2020 Jan; 22(1):83-90. PubMed ID: 31239188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromogranin A: A Valuable Serum Diagnostic Marker for Non-Insulinoma Neuroendocrine Tumors of the Pancreas in a Chinese Population.
    Hong L; Wang Y; Zhang T; Zhang C; Wang L; Wang L; Wang Z; Zhong J
    Med Sci Monit; 2020 Nov; 26():e926635. PubMed ID: 33141811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors.
    Hijioka M; Ito T; Igarashi H; Fujimori N; Lee L; Nakamura T; Jensen RT; Takayanagi R
    Cancer Sci; 2014 Nov; 105(11):1464-71. PubMed ID: 25220535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection.
    Modlin IM; Drozdov I; Alaimo D; Callahan S; Teixiera N; Bodei L; Kidd M
    Endocr Relat Cancer; 2014 Aug; 21(4):615-28. PubMed ID: 25015994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive Value of Chromogranin A and a Pre-Operative Risk Score to Predict Recurrence After Resection of Pancreatic Neuroendocrine Tumors.
    Fisher AV; Lopez-Aguiar AG; Rendell VR; Pokrzywa C; Rocha FG; Kanji ZS; Poultsides GA; Makris EA; Dillhoff ME; Beal EW; Fields RC; Panni RZ; Idrees K; Smith PM; Cho CS; Beems MV; Maithel SK; Winslow ER; Abbott DE; Weber SM
    J Gastrointest Surg; 2019 Apr; 23(4):651-658. PubMed ID: 30659439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Single-center Prospective Observational Study Investigating the Accuracy of Preoperative Diagnostic Procedures in the Assessment of Lymph Node Metastases in Nonfunctioning Pancreatic Neuroendocrine Tumors.
    Partelli S; Muffatti F; Andreasi V; Giannone F; Rossi G; Palumbo D; Mapelli P; Schiavo Lena M; Arcidiacono PG; De Cobelli F; Picchio M; Doglioni C; Falconi M
    Ann Surg; 2022 Nov; 276(5):921-928. PubMed ID: 35930017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.